We previously demonstrated that the administration of IL‐34 alone (.8 mg/kg/2 d) did not delay GVHD development compared to PBMC alone;9 thus, we used IL‐34 together with a suboptimal dose of rapamycin. This evidence concerns the gene IL34 and graft versus host disease.